Novel innate cancer killing activity in humans

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Blanks, Michael J ^a   Stehle Jr, John R ^a   Du, Wei ^a   Adams, Jonathan M ^a   Willingham, Mark C ^a   Allen, Glenn O ^b   Hu, Jennifer J ^b   Lovato, James ^a   Molnar, Istvan ^a   Cui, Zheng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ARTICLE; CANCER KILLING ACTIVITY; CANCER RISK; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INCUBATION TIME; INNATE IMMUNITY; LEUKOCYTE; MALE; RISK ASSESSMENT; TARGET CELL;

EID: 79961010190     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-26     Document Type: Article

References (29)

1. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909, 5:273-290.
2. Burnet FM. Immunological aspects of malignant disease. Lancet 1967, 1(7501):1171-1174.
3. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13:1-27.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3(11):991-998. 10.1038/ni1102-991, 12407406.
5. Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W, DeLong CJ. Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA 2003, 100(11):6682-6687. 10.1073/pnas.1031601100, 164507, 12724523.
6. Kloss S, Bochennek K, Huenecke S, Zimmermann S, Kuci S, Muller T, Wels W, Klingebiel T, Esser R, Koehl U. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells. J Immunol Methods 2007, 325(1-2):140-147. 10.1016/j.jim.2007.06.013, 17663991.
7. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000, 356(9244):1795-1799. 10.1016/S0140-6736(00)03231-1, 11117911.
8. Kim G, Donnenberg V, Donnenberg A, Gooding W, Whiteside T. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods 2007, 325(1-2):51-66. 10.1016/j.jim.2007.05.013, 2040258, 17617419.
9. Langhans B, Ahrendt M, Nattermann J, Sauerbruch T, Spengler U. Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J Immunol Methods 2005, 306(1-2):161-168. 10.1016/j.jim.2005.08.010, 16202423.
10. Strayer DR, Carter WA, Mayberry SD, Pequignot E, Brodsky I. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res 1984, 44(1):370-374.
11. Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA 2006, 103(20):7753-7758. 10.1073/pnas.0602382103, 1458507, 16682640.
12. Sanders A. Characterization of the inheritance, effector mechanisms, and response against endogenous cancers in the SR/CR mouse model of cancer resistance 2007, Winston-Salem: Wake Forest University Graduate School of Arts and Sciences.
13. Riedlinger G, Adams J, Stehle JR, Blanks MJ, Sanders AM, Hicks AM, Willingham MC, Cui Z. The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction. BMC Cancer 2010, 10(1):179. 10.1186/1471-2407-10-179, 2875217, 20438640.
14. Southam CM. Emotions, immunology, and cancer: how might the psyche influence neoplasia?. Ann N Y Acad Sci 1969, 164(2):473-475. 10.1111/j.1749-6632.1969.tb14063.x, 5260539.
15. van Rood Y, Goulmy E, Blokland E, Pool J, van Rood J, van Houwelingen H. Month-related variability in immunological test results; implications for immunological follow-up studies. Clin Exp Immunol 1991, 86(2):349-354. 1554130, 1834381.
16. Armario A, Marti O, Molina T, de Pablo J, Valdes M. Acute stress markers in humans: response of plasma glucose, cortisol and prolactin to two examinations differing in the anxiety they provoke. Psychoneuroendocrinology 1996, 21(1):17-24. 10.1016/0306-4530(95)00048-8, 8778900.
17. Nelson RJ, Demas GE, Klein SL, Kriegsfeld LJ. Seasonal Patterns of Stress, Immune Function, & Disease 2002, Cambridge University Press.
18. Nelson R, Demas G, Kriegsfeld L. Seasonal Patterns of Stress, Immune Function, & Disease 2002,
19. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116(3):544-573. 10.1002/cncr.24760, 19998273.
20. Brawley OW. Population categorization and cancer statistics. Cancer Metastasis Rev 2003, 22(1):11-19. 10.1023/A:1022244618834, 12716032.
21. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008, 8(9):737-744. 10.1038/nri2394, 18728636.
22. Nilsson N, Carlsten H. Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cell Immunol 1994, 158(1):131-139. 10.1006/cimm.1994.1262, 8087860.
23. Harkonen PL, Vaananen HK. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci 2006, 1089:218-227. 10.1196/annals.1386.045, 17261769.
24. Cui Z. The winding road to the discovery of the SR/CR mice. Cancer Immun 2003, 3:14.
25. Cui Z, Willingham M. The effect of aging on cellular immunity against cancer in SR/CR mice. Cancer Immunol Immunother 2004, 53(6):473-478. 10.1007/s00262-003-0488-2, 14730401.
26. Hicks A, Willingham M, Du W, Pang C, Old L, Cui Z. Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. Cancer Immun 2006, 6:11.
27. Stehle JR, Blanks MJ, Riedlinger G, Kim-Shapiro JW, Sanders AM, Adams JM, Willingham MC, Cui Z. Impact of sex, MHC, and age of recipients on the therapeutic effect of transferred leukocytes from cancer-resistant SR/CR mice. BMC Cancer 2009, 9:328. 10.1186/1471-2407-9-328, 2749872, 19754973.
28. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996, 88(8):496-509. 10.1093/jnci/88.8.496, 8606378.
29. Shibata A, Whittemore AS. Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate 1997, 32(1):65-72. 10.1002/(SICI)1097-0045(19970615)32:1<65::AID-PROS9>3.0.CO;2-B, 9207959.